Convenia 80 mg/ml Powder and Solvent for Solution for Injection for Dogs and Cats

Cross-resistance has been shown between cefovecin and other cephalosporins and
other -lactam antibiotics. Use of the veterinary medicinal product should be
carefully considered when susceptibility testing has shown resistance to
cephalosporins or -lactams because its effectiveness may be reduced.

Special precautions for use in animals
Use of the product should be based on identification and susceptibility testing of the
target pathogen(s). If this is not possible, therapy should be based on
epidemiological information and knowledge of susceptibility of the target pathogens
at local/regional level. Use of the product should be in accordance with official,
national and regional antimicrobial policies.
An antibiotic with a lower risk of antimicrobial resistance selection (lower AMEG
category) should be used for first line treatment where susceptibility testing suggests
the likely efficacy of this approach.
The product selects for resistant strains such as bacteria carrying extended-
spectrum beta-lactamases (ESBL) and may constitute a risk to human health if these
strains disseminate to humans.
The fundamental requirement of the treatment of periodontal disease is mechanical
and/or surgical intervention by the veterinarian.
The safety of the veterinary medicinal product has not been assessed in animals
suffering from severe renal dysfunction.

Amended pages: March 2025
AN: 02825/2023 & AN: 01472/2024
Pyoderma is often secondary to an underlying disease. It is, therefore, advisable to
determine the underlying cause and to treat the animal accordingly.
Caution should be exercised in patients that have previously shown hypersensitivity
reactions to cefovecin, other cephalosporins, penicillins, or other medicinal products.
If an allergic reaction occurs, no further administrations of cefovecin should be
administered and appropriate therapy for beta-lactam hypersensitivity should be
instituted. Serious acute hypersensitivity reactions may require treatment with
epinephrine and other emergency measures, including oxygen, intravenous fluids,
intravenous antihistamine, corticosteroids, and airway management, as clinically
indicated. Veterinarians should be aware that reappearance of the allergic symptoms
may occur when symptomatic therapy is discontinued.
Occasionally, cephalosporins have been associated with myelotoxicity, thereby
creating a toxic neutropenia. Other haematological reactions seen with
cephalosporins include neutropenia, anaemia, hypoprothrombinemia,
thrombocytopenia, prolonged prothrombin time (PT) and partial thromboplastin time
(PTT), platelet dysfunction.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Penicillins and cephalosporins may cause hypersensitivity (allergy) following
injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead
to cross sensitivity to cephalosporins and vice versa. Allergic reactions to these
substances may occasionally be serious.
Do not handle this product if you know you are sensitised or if you have been
advised not to work with such preparations.
Handle this product with care to avoid exposure, taking all recommended
precautions.
If you develop symptoms following exposure, such as a skin rash, you should seek
medical advice and show the doctor this warning. Swelling of the face, lips or eyes or
difficulty in breathing are more serious symptoms and require urgent medical
attention.
If you know you are allergic to penicillins or cephalosporins, avoid contact with
contaminated litter. In the event of contact, wash skin with soap and water.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.

Amended pages: March 2025
AN: 02825/2023 & AN: 01472/2024